Article | Published:

Synthesis of a poly(vinylpyrrolidone-co -dimethyl maleic anhydride) co-polymer and its application for renal drug targeting

Nature Biotechnology volume 21, pages 399404 (2003) | Download Citation

Subjects

Abstract

We have synthesized a polymeric drug carrier, polyvinylpyrrolidone-co-dimethyl maleic anhydride [poly(VP-co-DMMAn)], for use in renal drug delivery. About 80% of the 10-kDa poly(VP-co-DMMAn) selectively accumulated in the kidneys 24 h after intravenous administration to mice. Although this accumulated poly(VP-co-DMMAn) was gradually excreted in the urine, about 40% remained in the kidneys 96 h after treatment. Poly(VP-co-DMMAn) was taken up by the renal proximal tubular epithelial cells and no cytotoxicity was noted. Higher doses did not produce toxicity in the kidneys or other tissues. In contrast, polyvinylpyrrolidone of the same molecular weight did not show any tissue-specific distribution. Poly(VP-co-DMMAn)-modified superoxide dismutase accumulated in the kidneys after intravenous administration and accelerated recovery from acute renal failure in a mouse model. In contrast, polyvinylpyrrolidone-modified superoxide dismutase and native superoxide dismutase were not as effective. Thus, poly(VP-co-DMMAn) is a useful candidate as a targeting carrier for renal drug delivery systems.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey. Am. J. Kidney Dis. 32, 992–999 (1998).

  2. 2.

    Progress and Priorities: Renal disease research plan. Report of the strategic planning conferences, Renal research properties- sponsored by National Institute of Diabetes and Digestive and Kidney Disease, Council of American Kidney Societies, (December 5–6, 1998 & February 4–5, 1999). ()

  3. 3.

    , , , & Targeting 6-thioguanine to the kidney with S-(guanin-6-yl)-L-cysteine. J. Pharmacol. Exp. Ther. 274, 1298–1304 (1995).

  4. 4.

    et al. Potentials and limitations of the low-molecular-weight protein lysozyme as a carrier for renal drug targeting. Ren. Fail. 23, 397–409 (2001).

  5. 5.

    , , , & Renal accumulation of streptavidin: Potential use for targeted therapy to the kidney. Kidney Int. 47, 1327–1335 (1995).

  6. 6.

    , , & Synthesis of a superoxide dismutase derivative that circulates bound to albumin and accumulates in tissues whose pH is decreased. Biochemistry 28, 6619–6624 (1989).

  7. 7.

    , , & The renal excretion and retention of macromolecules: The chemical structure effect. Pflugers Arch. 392, 211–217 (1982).

  8. 8.

    , & α-Melanocyte-simulating hormone and interleukin-10 do not protect the kidney against mercuric chloride-induced injury. Am. J. Physiol. Renal Physiol. 282, F795–801 (2002).

  9. 9.

    et al. Antibodies to both ICAM-1 and LFA-1 do not protect the kidney against toxic (HgCl2) injury. Kidney Int. 58, 1121–1134 (2000).

  10. 10.

    et al. Synthesis and pharmacokinetics of a new liver-specific carrier, glycosylated carboxymethyl-dextran, and its application to drug targeting. Pharm. Res. 10, 1253–1261 (1993).

  11. 11.

    Cellular aspects of transcapillary exchange. Physiol. Rev. 63, 1536–1579 (1983).

  12. 12.

    , , & Permselectivity of the glomerular capillary wall: III. Restricted transport of polyanions. Kidney Int. 8, 212–218 (1975).

  13. 13.

    et al. Megalin-mediated endocytosis of transcobalamin-vitamin-B12 complexes suggests a role of the receptor in vitamin-B12 homeostasis. Proc. Natl. Acad. Sci. USA 93, 8612–8617 (1996).

  14. 14.

    , & Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney. J. Biol. Chem. 272, 30088–30095 (1997).

  15. 15.

    , , & Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am. J. Physiol. 276, F122–128 (1999).

  16. 16.

    et al. Developmental changes in multispecific organic anion transporter 1 expression in the rat kidney. Kidney Int. 57, 1608–1616 (2000).

  17. 17.

    & Dimethylmaleic anhydride, a specific reagent for protein amino groups. Biochem. Cell Biol. 67, 63–66 (1989).

  18. 18.

    & Effects of temperature and pH on the regeneration of the amino groups of ovalbumin after modification with citraconic and dimethylmaleic anhydrides. Biochim. Biophys. Acta 749, 204–210 (1983).

  19. 19.

    et al. Antitumor activity of tumor necrosis factor alpha conjugated with divinyl ether and maleic anhydride copolymer on solid tumors in mice. Cancer Res. 58, 290–295 (1998).

  20. 20.

    et al. Molecular design of conjugated tumor necrosis factor-alpha: synthesis and characteristics of polyvinyl pyrrolidone modified tumor necrosis factor-alpha. Biochem. Biophys. Res. Commun. 257, 448–453 (1999).

  21. 21.

    et al. Selective enhancement of thrombopoietic activity of PEGylated interleukin 6 by a simple procedure using a reversible amino-protective reagent. Br. J. Haematol. 112, 181–188 (2001).

  22. 22.

    et al. PEGylation of interleukin-6 effectively increases its thrombopoietic potency. Thromb. Haemost. 77, 168–173 (1997).

  23. 23.

    et al. Bioconjugation of laminin-related peptide YIGSR with polyvinyl pyrrolidone increases its antimetastatic effect due to a longer plasma half-life. Biochem. Biophys. Res. Commun. 264, 763–767 (1999).

  24. 24.

    et al. Antitumor activity of tumor necrosis factor-α conjugated with polyvinylpyrrolidone on solid tumors in mice. Cancer Res. 60, 6416–6420 (2000).

  25. 25.

    et al. Molecular design of polyvinylpyrrolidone-conjugated interleukin-6 for enhancement of in vivo thrombopoietic activity in mice. J. Control. Release. 68, 335–341 (2000).

  26. 26.

    et al. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc. Natl. Acad. Sci. USA 97, 8548–8553 (2000).

  27. 27.

    et al. Molecular design of hybrid tumour necrosis factor α with polyethylene glycol increases its anti-tumour potency. Br. J. Cancer 71, 963–968 (1995).

  28. 28.

    , , , & Liposomal formulations of Cu,Zn-superoxide dismutase: physico-chemical characterization and activity assessment in an inflammation model. J. Control. Release 43, 1–8 (1997).

  29. 29.

    , , & Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation. Adv. Drug. Deliv. Rev. 54, 587–606 (2002).

Download references

Acknowledgements

We thank Ira Pastan for advice, discussion, and assistance. This study was supported in part by a Grant-in-Aid for Scientific Research (13672385) from the Ministry of Education, Science and Culture of Japan, and in part by Health Sciences Research Grants for Research on Health Sciences focusing on Drug Innovation from the Japan Health Sciences Foundation (KH63124).

Author information

Author notes

    • Haruhiko Kamada
    •  & Yasuo Tsutsumi

    These authors contributed equally to this work.

Affiliations

  1. Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.

    • Haruhiko Kamada
    • , Yasuo Tsutsumi
    • , Keiko Sato-Kamada
    • , Yoko Yamamoto
    • , Yasuo Yoshioka
    • , Takayuki Okamoto
    • , Shinsaku Nakagawa
    •  & Tadanori Mayumi
  2. Laboratory of Molecular Biology (Ira Pastan's Laboratory), Division of Basic Science, National Cancer Institute, National Institutes of Health, Building 37, Room 4E16, 37 Convent Drive MSC 4255, Bethesda, MD 20892-4255.

    • Satoshi Nagata

Authors

  1. Search for Haruhiko Kamada in:

  2. Search for Yasuo Tsutsumi in:

  3. Search for Keiko Sato-Kamada in:

  4. Search for Yoko Yamamoto in:

  5. Search for Yasuo Yoshioka in:

  6. Search for Takayuki Okamoto in:

  7. Search for Shinsaku Nakagawa in:

  8. Search for Satoshi Nagata in:

  9. Search for Tadanori Mayumi in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Yasuo Tsutsumi.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nbt798

Further reading